C. Page (London, United Kingdom), M. Cazzola (Rome, Italy)
A dual-acting muscarinic antagonist, ß2-agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial
P.L.M.L. Wielders, A. Ludwig-Sengpiel, N.W. Locantore, S.F. Baggen, R.H. Chan, J.H. Riley (Eindhoven, Zeist, Netherlands; Luebeck, Germany; Reasearch Triangle Park, United States Of America; Uxbridge, United Kingdom)
|  |
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment
E.M. Kerwin, C. Scott-Wilson, L. Sanford, S.I. Rennard, A. Agusti, N. Barnes, C. Crim (Medford, Uxbridge, London, United Kingdom; Research Triangle Park, Omaha, United States Of America; Barcelona, Spain)
| |
The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
A.M. Kirsten, K. Förster, E. Radeczky, A. Linnhoff, B. Balint, H. Watz, H. Wray, L. Salkeld, M. Cullberg, H. Lam, B. Larsson (Grosshansdorf, Berlin, Germany; Százhalombatta, Deszk, Hungary; Mölndal, Södertälje, Sweden)
| |
Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma
R. Sutherland, K. Tetzlaff, C. Nivens, M. Tsukayama, A. Guerreros, R. Manuel, E. Bateman, J. Blatchford, A. Fowler, A. Gupta (Denver, Ridgefield, United States Of America; Biberach an der Riss, Germany; Lima, Peru; Cape Town, South Africa; Bracknell, United Kingdom)
| |
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
A. Fowler, D. Miller, C. LaForce, A. Finn, E. Bateman, K. Drda, J. Blatchford, W. Broderick, A. Gupta, C. Wood (North Dartmouth, Raleigh, North Charleston, Ridgefield, United States Of America; Cape Town, South Africa; Bracknell, United Kingdom; Biberach an der Riss, Germany)
| |
Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma
B. Leaker, D. Singh, S. Lindgren, G. Almqvist, B. Young, B. O‘Connor (London, , Charnwood, Loughborugh, United Kingdom; Mölndal, Sweden)
| |
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
G. Gauvreau, L.P. Boulet, D. Cockcroft, B. Davis, M. Fitzgerald, R. Leigh, B. Dahlen, I. Mayers, H. Scheerens, R. Maciuca, J. Matthews, J. Harris, P. O‘Byrne (Ontario, Quebec, Saskatoon, Vancouver, Canada; Stockholm, Sweden; San Francisco, United States Of America)
| |